SCHEMBL15747657

SCHEMBL15747657

NC(=O)c1ccc2cncc(-c3ccc(Cl)cc3Cl)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 3/20 0.49
CDK8 P49336 3/20 0.49
DPP4 P27487 3/20 0.48
DPP8 Q6V1X1 3/20 0.48
CDC7 O00311 2/20 0.41
CCNE1 P24864 2/20 0.41
CDK2 P24941 2/20 0.41
DBF4 Q9UBU7 2/20 0.41
PIM1 P11309 1/20 0.38
GRM2 Q14416 3/20 0.38
CNR1 P21554 4/20 0.38
MARS1 P56192 1/20 0.37
MAP4K4 O95819 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.36
CCNT1 O60563 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK1A1 P48729 1/20 0.36
CSNK1D P48730 1/20 0.36
CDK9 P50750 1/20 0.36
CSNK2B P67870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15742904 0.84 CCNC (0.51) CCNCCDK8PIM1GRM2CNR1
SCHEMBL15742865 0.82 CCNC (0.65) CCNCCDK8PIM1GRM2MAP4K4
SCHEMBL16719104 0.82 DPP4 (0.46) CDK8DPP4DPP8CDC7CCNE1
SCHEMBL15742786 0.81 CCNC (0.54) CCNCCDK8PIM1MAP4K4
SCHEMBL15742724 0.77 CNR1 (0.42) CCNCCDK8CNR1
SCHEMBL16212390 0.76 MAP4K4 (0.46) DPP4DPP8CDC7CCNE1CDK2
SCHEMBL15742884 0.76 CCNC (0.55) CCNCCDK8GRM2
SCHEMBL15742900 0.75 CCNC (0.59) CCNCCDK8PIM1GRM2
SCHEMBL15742765 0.74 CCNC (0.58) CCNCCDK8PIM1GRM2
SCHEMBL4580346 0.73 CCNC (0.64) CCNCCDK8CDK2PIM1CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657014-B2 Substituted 1,6-naphthyridines HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US claimed
US-20150252044-A1 SUBSTITUTED 1,6-NAPHTHYRIDINES HOFFMANN-LA ROCHE INC. (US) 2015-09-10 US claimed
US-9657014-B2 Substituted 1,6-naphthyridines HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
US-9657014-B2 Substituted 1,6-naphthyridines HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
US-9657014-B2 Substituted 1,6-naphthyridines HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
US-20150252044-A1 SUBSTITUTED 1,6-NAPHTHYRIDINES HOFFMANN-LA ROCHE INC. (US) 2015-09-10 US disclosed
US-20150252044-A1 SUBSTITUTED 1,6-NAPHTHYRIDINES HOFFMANN-LA ROCHE INC. (US) 2015-09-10 US disclosed
US-20150252044-A1 SUBSTITUTED 1,6-NAPHTHYRIDINES HOFFMANN-LA ROCHE INC. (US) 2015-09-10 US disclosed
WO-2014079787-A1 SUBSTITUTED 1,6-NAPHTHYRIDINES F. HOFFMANN-LA ROCHE AG (CH) 2014-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252044-A1 SUBSTITUTED 1,6-NAPHTHYRIDINES CBR3, CBR1, NR2C2 CCNC 1270/4885CDK8 3289/4885DPP4 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.